Results 131 to 140 of about 34,076,848 (256)

Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats. [PDF]

Int J Mol Sci, 2023
Tornling G, Batta R, Salvail D, Raud J, Denton CP.   +4 more
europepmc   +1 more source

Angiotensin converting enzyme and vascular endothelial growth factor responses to exercise training in claudicants: the role of ace inhibition [PDF]

, 2009
Exercise training is well recognised as an effective treatment for intermittent claudication. The mechanism underlying exercise induced improvements is multi-factorial but remains poorly understood.
Ng, P.
core  

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats. [PDF]

Sci Rep, 2023
Kulkarni K, Patel S, Ali R, Hussain T.
europepmc   +1 more source

ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease

, 2010
T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, LibyaAbstract:
K Bharani, K Gauthaman, T S Mohamed Saleem   +2 more
core  

Osteoprotegerin: a pancreatic islets dysfunction and vascular injury modulator [PDF]

, 2011
Background. Osteoprotegerin (OPG) is a soluble glycoprotein of the tumor necrosis factor (TNF) receptor superfamily, which was initially identified as a key regulator in bone turnover.
Toffoli, Barbara
core  

Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current

, 2004
Objective: The Ca2+ -independent transient outward K+ current (Ito) plays a crucial role in shaping the cardiac action potential. In the present study, we examined whether angiotensin II (AngII) regulated the Ito as well as the putative intracellular ...
Tamargo Menéndez, Juan, Arias, Cristina, Valenzuela, Carmen, Guizy, Miriam, Delpón Mosquera, María Eva, Moreno, Fernández, Ignacio, González, Teresa, Caballero Collado, Ricardo, Gómez García, Ricardo, Núñez Fernández, Lucía   +9 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Inhibition of the angiotensin II type 2 receptor AT₂R is a novel therapeutic strategy for glioblastoma. [PDF]

Proc Natl Acad Sci U S A, 2022
Perryman R, Renziehausen A, Shaye H, Kostagianni AD, Tsiailanis AD, Thorne T, Chatziathanasiadou MV, Sivolapenko GB, El Mubarak MA, Han GW, Zarzycka B, Katritch V, Lebon G, Lo Nigro C, Lattanzio L, Morse SV, Morse SV, Choi JJ, O'Neill K, Kanaki Z, Klinakis A, Crook T, Cherezov V, Tzakos AG, Syed N.   +24 more
europepmc   +1 more source